AstraZeneca Pharmaceuticals LP
NEWS
AstraZeneca reported first-quarter financials, with Product Sales growing 10% (14% at CER) to $5.465 billion. What is more startling, and completely in accordance with the company’s stated goals, Global Oncology sales increased by 54%.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
The two companies will focus on utilizing the microbiome, all the bacteria, viruses and fungi in the body, to improve cancer immunotherapy.
JOBS
IN THE PRESS